InflaRx, a Jena and Munich, Germany-based biopharmaceutical company developing new therapeutics in the terminal complement space, raised $55M in Series D funding.
The round, comprised of a $30M capital increase and a $ 25M secondary share purchase, was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a US investment management firm.
The company intends to use the funds to advance clinical phase IIb development of its lead drug candidate IFX-1, a anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance preclinical development of follow-up pipeline molecules.
Founded in 2007, InflaRx focuses on applying its proprietary anti-C5a technology to discover and develop specific inhibitors of C5a, an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The company is also developing additional molecules targeting chronic and inflammation-related diseases.
In July 2017, InflaRx completed a clinical Phase IIa open label trial in patients suffering from Hidradenitis Suppurativa, a chronic debilitating auto-inflammatory skin disease, which demonstrated the disease modifying activity of lead drug candidate IFX-1.
The company has been previously financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group, Staidson Hongkong Investment Co Ltd, and various international family and industrial investment offices.